Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Beclometasone oral - Soligenix

Next Previous
X
Search
Drug Profile

Beclometasone oral - Soligenix

Alternative Names: BDP; DOR 201; DOR 202; DOR 203; Oral BDP - Soligenix/Sigma-Tau; Oral beclomethasone 17,21-dipropionate; orBec; OrbeShield; SGX 201; SGX 202; SGX 203

Latest Information Update: 27 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Enteron Pharmaceuticals
  • Developer Fred Hutchinson Cancer Research Center; National Institutes of Health (USA); Soligenix
  • Class Anti-inflammatories; Antiallergics; Antiasthmatics; Chlorinated steroids; Corticosteroids; Pregnadienetriols; Small molecules; Vascular disorder therapies
  • Mechanism of Action Immunosuppressants; Steroid receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Crohn's disease; Graft-versus-host disease; Acute radiation syndrome
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase I/II Crohn's disease; Radiation injuries
  • No development reported Acute radiation syndrome
  • Discontinued Graft-versus-host disease

Most Recent Events

  • 31 Dec 2022 Soligenix has patent protection for beclomethasone including Australia, Canada, China, Hong Kong, Israel, Japan, South Korea and New Zealand
  • 31 Dec 2022 Soligenix has patent pending for beclomethasone in Australia, Canada, China, Hong Kong, Israel, Japan, South Korea and New Zealand
  • 30 Mar 2021 Soligenix has patent protection and patent pending for Oral beclomethasone for radiation and chemotherapy injuries in Australia, Canada, China, Hong Kong, Israel, Japan, South Korea and New Zealand before March 2021

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top